The iShares Core Dividend Growth ETF (DGRO) is recommended as a buy due to its strong financial sector allocation, which benefits from rising interest rates and solid bank earnings expected to boost dividends. The ETF's dividend growth is projected to exceed its recent 5.42% annual growth rate, with a conservative 2026 payout estimate of $1.57 per share, an 8.2% increase year-over-year. DGRO also offers lower volatility with a low beta and balanced exposure to technology and healthcare sectors, allowing investors to participate in AI-driven market trends while managing risk.
The iShares Core Dividend Growth ETF (DGRO) is highlighted with a projected 8.2% year-over-year dividend increase in 2026. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 02, 2026 04:11 WIB: out of 85 priced Financials-sector US stocks tradable on Pluang, 39 rose and 46 fell today. Notable price points include GEMI at USD 5.06 with 100% buy order activity, GPN at USD 81.76 also with 100% buy order activity, and KKR at USD 91.45 with 100% sell order activity.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
